Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $7.60 Consensus Target Price from Analysts

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been assigned a consensus recommendation of “Hold” from the six analysts that are currently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $7.60.

A number of analysts recently weighed in on the stock. Needham & Company LLC decreased their price target on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, May 6th. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Leerink Partners dropped their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Friday, February 28th. Finally, Morgan Stanley lowered their price objective on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 10th.

Recursion Pharmaceuticals Trading Up 0.5%

Shares of Recursion Pharmaceuticals stock opened at $4.39 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. Recursion Pharmaceuticals has a 1 year low of $3.79 and a 1 year high of $12.36. The company has a market capitalization of $1.78 billion, a P/E ratio of -2.87 and a beta of 0.99. The business has a 50 day moving average price of $4.84 and a 200 day moving average price of $6.37.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $14.75 million during the quarter, compared to analyst estimates of $18.12 million. During the same quarter last year, the firm posted ($0.39) earnings per share. The company’s revenue was up 7.2% on a year-over-year basis. Sell-side analysts anticipate that Recursion Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ensign Peak Advisors Inc boosted its stake in shares of Recursion Pharmaceuticals by 0.3% during the 4th quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company’s stock valued at $2,774,000 after buying an additional 1,300 shares during the period. Farther Finance Advisors LLC increased its holdings in shares of Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock worth $52,000 after purchasing an additional 1,353 shares during the period. Summit Investment Advisors Inc. increased its holdings in shares of Recursion Pharmaceuticals by 7.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company’s stock worth $176,000 after purchasing an additional 1,875 shares during the period. Clear Creek Financial Management LLC boosted its position in shares of Recursion Pharmaceuticals by 9.8% during the 1st quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company’s stock valued at $113,000 after acquiring an additional 1,907 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in Recursion Pharmaceuticals by 39.0% in the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock valued at $38,000 after buying an additional 2,026 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.